CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Theophyllinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02463409
NCT02463409Phase 2Completed
CompareCT.gov

Effects of Theophylline on cAMP Signaling in Children With Pseudohypoparathyroidism Type 1a

Vanderbilt University Medical Center·interventional·Posted Jun 4, 2015·Updated Jun 26, 2017

In Brief

A Phase 2 clinical trial evaluating Theophylline for Pseudohypoparathyroidism Type 1a and Albright Hereditary Osteodystrophy. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This study will test an investigational drug, theophylline, in children with pseudohypoparathyroidism type 1a (PHP1a). This study involves a 3 day visit to the Vanderbilt Clinical Research Center.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPseudohypoparathyroidism Type 1a, Albright Hereditary Osteodystrophy
CountriesUnited States
CollaboratorsMassachusetts General Hospital

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 4, 2015
Enrollment StartJun 1, 2015
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.1 years ago

Interventions

Theophyllinedrug

24 hour infusion of IV theophylline